Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.34 (
lipoprotein lipase
)
7,025
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Albumin carries fatty acids and has also been suggested to act as an antioxidant. In the present work, polyunsaturated fatty acids (linoleic, arachidonic, eicosapentaenoic and docosahexaenoic acids)--but not palmitic and oleic acid--inhibited growth of human hepatoma cells in low albumin concentration (0.5%). Growth inhibition by polyunsaturated fatty acids was prevented by albumin in a dose-related manner in the range 0.7-5.0%. Albumin also protected against growth inhibition following catabolism (by
lipoprotein lipase
) of very low density lipoproteins. Vitamin E strongly counteracted the inhibitory effect of polyunsaturated fatty acids. Vitamin E and albumin appeared to have additive effects in protecting against growth inhibition by polyunsaturated fatty acids.
Indomethacin
did not greatly modify the polyunsaturated fatty acids effect. Growth inhibition by polyunsaturated fatty acids, as well as the level of thiobarbituric acid reacting substances (a measure of lipid peroxidation) in growth media, increased with increasing number of fatty acids double bonds. Vitamin E and albumin prevented both thiobarbituric acid reacting substances formation and growth inhibition by polyunsaturated fatty acids. The results suggest that the concentrations of albumin and vitamin E in the incubation medium are essential when studying polyunsaturated fatty acids effects on cell growth.
...
PMID:Growth inhibition of human hepatoma cells (HepG2) by polyunsaturated fatty acids. Protection by albumin and vitamin E. 131 55
1
Indomethacin
(10(-4)M) causes marked augmentation of O-2 release from human neutrophils when these are stimulated by either 1,oleoyl-2,acetylglycerol or the divalent cation ionophore, A23187, the concentration-response curve for each agent being shifted to the left and the maximum response to each increased. 2 The diacylglycerol kinase inhibitor, R59022 (10(-5)M) has effects very similar to those of indomethacin on both the 1,oleoyl-2,acetylglycerol-induced and the A23187-induced concentration-response curves for O-2 generation. 3 The
diacylglycerol lipase
inhibitor, RHC80267 (10(-5 M) on the other hand, has a similar effect to indomethacin on 1,oleoyl-2,acetylglycerol-induced O2- generation but, unlike indomethacin, has no effect on A23187-induced O2- generation. Comparison of the effects of these three agents provides a clue to the locus of the action of indomethacin in increasing superoxide release, suggesting that it may act as a diacylglycerol kinase inhibitor. A component of
diacylglycerol lipase
inhibition may also be present. It is suggested that these results could have relevance for the use of indomethacin as an anti-inflammatory agent in chronic rheumatoid diseases.
...
PMID:Comparison of the effects of indomethacin, RHC80267 and R59022 on superoxide production by 1,oleoyl-2,acetyl glycerol and A23187 in human neutrophils. 282 95
4 h after intravenous injection of recombinant HuTNF-alpha to fed rats, an increase in heart, diaphragm, and plasma
lipoprotein lipase
activity was observed. At the same time, a 40-60% decrease in enzymic activity in epididymal fat pad and kidney and 40% decrease in hepatic lipase activity in liver had occurred. Similar results were obtained 20 h after injection of recombinant HuTNF-alpha into fasted rats. Pretreatment with
Indomethacin
did not affect the changes in tissue
lipoprotein lipase
activity observed following recombinant HuTNF-alpha administration. Serum triacylglycerol concentration increased by 2- and 6-fold; 4 and 20 h after recombinant HuTNF-alpha administration. Disappearance of 14C-labeled triacylglycerol from the circulation after injection of small chylomicrons, biosynthetically labeled in their triacylglycerol and cholesterol moieties, was lower in TNF-treated than in control rats. However, the clearance rate of triacylglycerol was the same or even higher in recombinant HuTNF-alpha treated rats (assuming that 14C-labeled chylomicron triacylglycerol represents the serum triacylglycerol pool). The livers of recombinant HuTNF-alpha-treated rats and controls contained similar amounts of 14C-labeled lipids, but less [3H]cholesterol, suggesting that in recombinant HuTNF-alpha-treated rats, the liver took up chylomicron remnant particles enriched with triacylglycerol. Separation of the d less than 1.04 g/ml fraction of serum obtained from control and recombinant HuTNF-alpha treated rats by zonal ultracentrifugation revealed that in recombinant HuTNF-alpha-treated rats the lipoprotein particles were less lipolyzed than in controls. The secretion rate of [3H]triacylglycerol into the serum was determined 90 min after injection of [3H]palmitate albumin complex and Triton WR 1339. In recombinant HuTNF-alpha-treated rats, the secretion of [3H]triacylglycerol into plasma was 48% higher than in controls. It is suggested that the increase in
lipoprotein lipase
activity of heart and diaphragm resulted from an indirect effect of TNF. It is concluded that the increase in serum triacylglycerol in the recombinant HuTNF-alpha-treated rats is due mainly to an increased secretion of triacylglycerol by the liver. Impaired lipolysis, probably due to a fall in hepatic lipase could also contribute to the rise in plasma triacylglycerol.
...
PMID:Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. 291 56
The relative importance of several phospholipid pathways in cyclic AMP (cAMP) metabolism and growth hormone (GH) release was determined by an indirect, pharmacological approach in cultured anterior pituitary cells. The
diglyceride lipase
inhibitor RHC-80267 (30-100 microM) had no significant effect on cAMP levels but markedly inhibited basal and growth hormone-releasing factor-(GRF) stimulated GH secretion. A phospholipase A2 inhibitor quinacrine (30 microM) increased cellular cAMP content while decreasing GH release.
Indomethacin
, which reduces cyclooxygenase activity, affected neither cAMP levels nor GRF-enhanced GH release; this drug (30-100 microM) did reduce basal GH release. The lipoxygenase inhibitors nordihydroguaiaretic acid and BW-755c both reduced basal and GRF-stimulated GH release in a concentration-dependent manner. Both agents had various effects on cAMP levels. These results suggest that phospholipid metabolism, through both the cyclooxygenase and lipoxygenase pathways, contributes to basal GH release, while the lipoxygenase route predominates in GRF-stimulated GH release in vitro. Interestingly, cAMP metabolism can be dissociated from GH release with some of these probes, indicating an action of phospholipid metabolites distal or lateral to the cAMP-generating system.
...
PMID:Modification of basal and GRF-stimulated cyclic AMP levels and growth hormone release by phospholipid metabolic enzyme inhibitors. 298 27
The synthesis and secretion of prostaglandins and leukotrienes by mouse peritoneal macrophages is under several regulatory controls. Arachidonic acid must first be released from phospholipid stores by the action of phospholipases. Macrophages have the capacity to deacylate arachidonic acid directly from the SN2 position of phospholipids via the action of a phospholipase A2. In addition, these cells contain a phospholipase C capable of removing inositol-phosphate from phosphatidylinositol generating diacylglycerol. Another enzyme,
diacylglycerol lipase
is present to then generate arachidonic acid. The free arachidonic acid then enters the cyclooxygenase pathway to generate prostaglandins, the lipoxygenase pathway to generate leukotrienes or both pathways. The nature of the inflammatory stimulus added to these cells determines which of the above pathways become operative. Zymosan and the Ca++ ionophore, A23187 stimulate the synthesis of both prostaglandins and leukotrienes whereas phorbol myristate acetate and lipopolysaccharide induce only the synthesis of prostaglandins. In addition, the synthesis of these two products by macrophages can be regulated by certain antiinflammatory compounds.
Indomethacin
, aspirin, ibuprofen and benoxaprofen are only inhibitors of the prostaglandin pathway, whereas BW755C, 5,8,11-ETYA, NDGA and sulindac sulfide (high doses) are inhibitors of the synthesis of both prostaglandins and leukotrienes. Dapsone, an effective drug for leprosy, also inhibits the synthesis of both of these products.
...
PMID:Physiological and pharmacological regulation of prostaglandin and leukotriene production by macrophages. 632
Indomethacin
50 mg i.v. or p.o. and diclofenac sodium 50 mg p.o. produced a prompt and significant increase in plasma free fatty acid concentration. In 10 subjects who took indomethacin 150 mg/d p.o. for 3 days, plasma post-heparin
lipoprotein lipase
activity was also significantly increased. The same effect occurred in 9 subjects treated for 3 days with diclofenac sodium 50 mg t.d.s. Since both indomethacin and diclofenac sodium are potent inhibitors of prostaglandin synthetase, these findings are consistent with the hypothesis tht prostaglandins are involved in the feed-back regulation of lipolysis, and mediate the inhibitory effect of lipolysis on
lipoprotein lipase
activity.
...
PMID:Influence of two non-steroidal anti-inflammatory drugs on lipolysis and on plasma post-heparin lipoprotein lipase activity in normal man. 679 23
Human platelets incubated with thrombin and indomethacin (50 microgram/ml) exhibit an accumulation of diglyceride larger and more persistent than that observed for platelets incubated with thrombin alone. The accumulation appears to be due to the impaired metabolism of diglyceride by
diglyceride lipase
. In preparations of broken platelets, indomethacin leads to inhibition of
diglyceride lipase
. A similar inhibition can be achieved by the addition of soybean lipoxidase, and both inhibitions can be counteracted by reduced glutathione. Further, hydroperoxyeicosatetraenoic acid (100 microM) markedly depresses
diglyceride lipase
activity, whereas neither the hydroxy derivative nor eicosatetraenoic acid displays a comparable effect.
Indomethacin
at concentrations comparable to those impairing
diglyceride lipase
does not inhibit diglyceride kinase. This report constitutes the first evidence for the functioning of
diglyceride lipase
in normal stimulated platelets, and points to a possible role for fatty acid hydroperoxides in governing the activity of this enzyme.
...
PMID:Indomethacin-induced accumulation of diglyceride in activated human platelets. The role of diglyceride lipase. 735 67
1. The effects of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD), a non-selective agonist of the metabotropic glutamate receptors (mGluRs), have been studied in rat cortical and striatal slices by measuring the depolarization-induced output of D-[3H]-aspartate (D-[3H]-Asp) and of [3H]-glutamate ([3H]-Glu), neosynthesized from [3H]-glutamine. 2. In cortical slices, 1S,3R-ACPD potentiated the depolarization-induced (KCl, 30 mM) output of both D-[3H]-Asp and [3H]-Glu. The potentiation, obtained at 300 microM 1S,3R-ACPD was 65 +/- 6% for D-[3H]-Asp and 56 +/- 10% for [3H]-Glu. Conversely, in striatal slices, 1S,3R-ACPD reduced the depolarization-induced transmitter output. The reduction, obtained at 300 microM of the agonist, was 60 +/- 8% for D-[3H]-Asp and 50 +/- 5% for neosynthesized [3H]-Glu. 3. Bovine serum albumin (BSA, 15 microM), which is able to bind locally produced fatty acids, completely eliminated the potentiating effect 1S,3R-ACPD had on D-[3H]-Asp output from cortical slices. Low concentrations of arachidonic acid (1-10 microM) or of oleic acid (1-10 microM) added to BSA-containing perfusion medium, restored this potentiating effect. BSA, however, had no effect on the inhibitory action of 1S,3R-ACPD in striatal slices. 4. Bromophenacyl bromide (100 microM), an inhibitor of phospholipase A2, and RG80267 (100 microM), an inhibitor of
diacylglycerol lipase
, have been shown to inhibit fatty acid production. These compounds prevented the potentiating effect of 1S,3R-ACPD on D-[3H]-Asp-output in cortical slices. 5.
Indomethacin
(100 microM), an inhibitor of cyclo-oxygenases, plus nordihydroguaiaretic acid (100 microM), an inhibitor of lipoxygenases, increased D-[3H]-Asp output in cortical slices perfused with BSA-containing medium. 6. These experiments suggest that the mGluR-mediated potentiation of transmitter output requires the availability of unsaturated fatty acids, such as arachidonic or oleic acids, in cortical slices. In contrast, the mGluR-induced inhibition of transmitter output is not dependent upon fatty acid availability in striatal slices. The requirement of both unsaturated fatty acids and 1S,3R-ACPD in the facilitation of transmitter exocytosis may play an important role in the regulation of synaptic plasticity.
...
PMID:Metabotropic glutamate receptors, transmitter output and fatty acids: studies in rat brain slices. 882 62
Prostanoids are involved in the phenylephrine-induced contraction of the aorta. Here, we examined whether or not constitutive cyclooxygenase-2 (phosholipases C and A2) is the source of prostanoids in the smooth muscle of the arterial wall of the thoracic and abdominal aorta. Both cyclooxygenase isoforms (COX-1 and COX-2) were expressed in the two aortic segments, but their expression was not altered by phenylephrine, the protein synthesis inhibitor cycloheximide, or the phospholipase A2 inhibitors arachidonyl trifluoromethyl ketone and methyl arachidonyl fluorophosponate.
Indomethacin
and NS398, which are a non-selective and selective COX-2 inhibitor, respectively, but not SC-560, which is a COX-1-selective inhibitor, inhibited the effect of phenylephrine on the abdominal, but not the thoracic, aorta. Similarly, U73122, which is a phospholipase C inhibitor, and RHC80267, which is a
diacylglycerol lipase
inhibitor, inhibited the effect of phenylephrine. These findings suggest that prostanoids, which are produced by constitutively active COX-2, influence the contractile response of the abdominal aorta and that the production of arachidonic acid relies on phospholipase C and
diacylglycerol lipase
.
...
PMID:The influence of constitutive COX-2 in smooth muscle tissue on the contractile effect of phenylephrine in the rat abdominal aorta. 2003 91